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Background: Prior studies have found that smokers with STEMI have lower mortality rates and a more
favorable response to fibrinolytic therapy than nonsmokers, phenomenon defined as “the smoker’s
paradox”. Still poorly explored is the impact of cigarette smoking in patients undergoing primary
percutaneous coronary intervention. Aim of the current study was to evaluate the impact of cigarette
smoking on scintigraphic infarct size in STEMI patients undergoing primary PCI.
Methods: Our population is represented by 830 STEMI patients undergoing primary PCI. Infarct size was
evaluated at 30 days by technetium-99m-sestamibi.
Results: Smoking was associated with younger age (p < 0.001), a lower prevalence of female gender
(p < 0.001), hypertension (p < 0.001), diabetes (p ¼ 0.003), shorter ischemia time (p ¼ 0.037), but higher
rates of previous PCI (p ¼ 0.016). No differences were observed in other clinical or angiographic char-
acteristics. In particular, smoking did not affect the rate of postprocedural TIMI 3 flow. As shown in Fig. 1,
smoking did not affect infarct size (12.5% [3.3%e23.7%] vs 12.7% [4.9%e25.9%], p ¼ 0.12). Similar results
were observed in subanalyses according to infarct location (anterior STEMI, p int ¼ 0.33), gender (p
int ¼ 0.95) age, (p Int ¼ 0.96), diabetes (p int ¼ 0.85). The absence of any impact of smoking on infarct
size was confirmed after correction for baseline characteristics, such as age, gender, hypertension, dia-
betes, previous PCI, ischemia time (OR [95% CI] ¼ 0.80 [0.59e1.09], p ¼ 0.15).
Conclusions: This study shows that among STEMI patients undergoing primary PCI smoking status does
not affect infarct size.
 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
It is well know that smoking is a major risk factors for coronary
artery disease (CAD), with significantly higher rates of ST-segment
elevation myocardial infarction (STEMI) and death [1e3]. Paradox-
ically, despite the increased occurrence of STEMI in active smokers,
prior studies have found that the mortality rate of smokers after
STEMI is lower than in nonsmokers [4e7], especially after fibrino-
lytic therapy [8e12]. This phenomenon, defined as “the smoker’s
paradox”, has been partly explained by fewer coexisting high-risk
features in patients with STEMI who are current smokers [6e12].
In addition, is has been supposed a difference in lesion compositionx: þ39 0321 3733407.
novara.it, p.de_luca@libero.it
nd Ltd. All rights reserved.with a greater thrombotic component and relatively less athero-
sclerotic plaque burden in smokers [10], thereby contributing to the
more benign long-term prognosis in these patients.
The impact of cigarette smoking on clinical outcome in patients
undergoing primary percutaneous coronary intervention has not
been largely investigated. In particular, the supposed higher
thrombotic component may be associated with impaired reperfu-
sion and larger infarct size when a mechanical reperfusion is per-
formed. Therefore, the aim of the current study was to evaluate
whether cigarette smoking does affect scintigraphic infarct size
among STEMI patients undergoing primary angioplasty.2. Materials and methods
Our population is represented by 830 STEMI patients treated by
primary angioplasty, who were included in randomized trials
Table 1
Demographic and clinical characteristics according to history of smoking.
Variable Smoking (n ¼ 401) Control (n ¼ 429) p value
Age 61 [53e69] 67 [59e75] <0.001
Age >75 ys (%) 7.2 32.2 <0.001
Female gender (%) 14 27.3 <0.001
Hypertension (%) 33.7 52.9 <0.001
Dyslipidemia (%) 33.4 34.5 0.74
Diabetes (%) 10.2 17.2 0.003
Previous ACS (%) 5 3.3 0.21
Previous CABG (%) 0.7 0.9 1.0
Previous PTCA (%) 5.2 2.1 0.016
Ischemia time (minutes) 195 [140e269] 210 [155e280] 0.037
Ischemia time >3 h (%) 55.4 62.9 0.03
Anterior MI (%) 36.9 43.1 0.068
Cardiogenic shock (%) 3.0 4.9 0.16
Table 2
Angiographic and procedural characteristics according to history of smoking.
Variable Smoking (n ¼ 401) Control (n ¼ 429) p value
Collateral circulation 0.6
RENTROP 0 (%) 89.8 88.8
RENTROP 1 (%) 6.4 7.8
RENTROP 2 (%) 3.8 2.7
RENTROP 3 (%) 0 0.8
Preprocedural TIMI 3 flow (%) 7.5 8.6 0.56
IRA 0.25
RCA (%) 47.4 43.4
CX (%) 15.5 13.3
Graft (%) 0 0.1
LAD (%) 36.9 43.1
LM (%) 0 0.2
Multivessel disease (%) 39.8 43.0 0.36
Abciximab (%) 91.5 88.6 0.16
Stenting (%) 100 98 0.95
DES (%) 5.7 6.2 0.94
Direct Stenting (%) 76 77.2 0.78
Thrombectomy (%) 42.4 41 0.75
IABP (%) 3.0 4.9 0.16
Postprocedural TIMI 3 flow (%) 91.0 93.4 0.19
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infarct size at 30 days after intervention [13e15]. All patients were
admittedwithin 12 h from symptom onset, and received at the time
of diagnosis aspirin (500 mg intravenously) and heparin (60 IU/Kg
intravenously), as much as beta-blockers and nitroglycerine intra-
venously if not contraindicated, whereas the decision to provide
glycoprotein IIb-IIIa inhibitors was left at the discretion of the
operator at the time of intervention. All patients were on dual oral
antiplatelet therapy (aspirin and clopidogrel or ticlopidine) for at
least 4 weeks after stent implantation. All demographic, clinical,
procedural and in-hospital and follow-up data were collected in a
database.
2.1. Coronary angiography and mechanical revascularization
Selective coronary angiography was performed in multiple
projections before mechanical reperfusion. Immediately after
diagnostic angiography, percutaneous coronary intervention with
stenting of the infarct-related vessel was performed using standard
material. Successful primary percutaneous coronary intervention
was defined as Thrombolysis In Myocardial Infarction (TIMI) grade
3 coronary flow in the treated vessel with a residual stenosis <20%.
2.2. Infarct size assessment
As previously described [15], gated single-photon emission
computed tomography (SPECT) acquisition began 60 min after
technetium-99m-sestamibi injection (740 MBq), using a double-
head gamma-camera equipped with high-resolution collimators,
180 rotation arc, 32 projections, 60 s/projection, 8 frames/heart
cycle and 64  64 matrices. The studies were reconstructed using
filtered back-projection without attenuation or scatter correction
and realigned along the heart axis. Perfusion defects were quanti-
fied as percentage of LV wall, with the defect threshold set at 60% of
peak uptake [16].
2.3. Statistical analysis
Statistical analysis was performed with the SPSS 17.0 statistical
package. Continuous data were expressed as median [25e75th
percentiles] and categorical data as percentage. The analysis of
variance test (ANOVA) or ManneWhitney U test was appropriately
used for continuous variables, according to the normality of dis-
tribution, as evaluated by the ShapiroeWilk test. The chi-square
test or the Fisher’s exact test was used for categorical variables.
Multiple logistic regression analysis was used to evaluate the
impact of smoking on infarct size after adjustment for significant
(p < 0.05) confounding baseline characteristics. A propensity score
analysis was performed in order to evaluate the impact of smoking
on infarct size in homogeneous subgroups of patients.
3. Results
Patients’ characteristics are shown in Tables 1 and 2. Smoking
was associated with younger age (p < 0.001), a lower prevalence of
female gender (p < 0.001), hypertension (p < 0.001), diabetes
(p ¼ 0.003), shorter ischemia time (p ¼ 0.037), but higher rates of
previous PCI (p ¼ 0.016). No differences were observed in other
clinical or angiographic characteristics. In particular, smoking did
not affect the rate of postprocedural TIMI 3 flow. As shown in Fig. 1,
smoking did not affect infarct size (12.5% [3.3%e23.7%] vs 12.7%
[4.9%e25.9%], p ¼ 0.12).
Similar results were observed according to tertiles of propensity
score (Fig. 2) and in subanalyses according to infarct location
(anterior STEMI: 9.6% [4.1%e25.1%] vs 10.2% [3.9%e22.7%], p¼ 0.34;non-anterior STEMI: 12.6% [3.2%e23.2%] vs 13.2% [5.3%e26.3%],
p ¼ 0.38; p int ¼ 0.33), gender (female gender: 11.6% [2%e20.3%] vs
11% [4%e22%], p ¼ 0.25; male gender: [14.5% [5.7%e28.6%] vs 16.1%
[6.0%e31.0%]], p ¼ 0.018; p int ¼ 0.95) age, (>65 years 12.9% [5%e
23.8%] vs 15.3% [6.5%e28%], p ¼ 0.18; <65 years: 3.6% [0e18.7%] vs
8.6% [0e19%], p ¼ 0.28; p int ¼ 0.96), diabetes (yes: 11.9% [1.8%e
23.8%] vs 12.4% [4.6%e23.8%], p ¼ 0.78; no: 12.6% [3.7%e23.6%] vs
15.0% [5.2%e27.4%], p¼ 0.067; p int¼ 0.85), without any significant
interaction for each variable.
The absence of any impact of smoking on infarct size was
confirmed when the analysis was conducted according to the per-
centage of patients with infarct size above the median (Fig. 3), even
after correction for baseline characteristics, such as age, gender,
hypertension, diabetes, previous PCI, ischemia time (OR [95%
CI] ¼ 0.80 [0.59e1.09], p ¼ 0.15).4. Discussion
This is the largest prospective study to date evaluating the
impact of cigarette smoking on infarct size among STEMI patients
undergoing mechanical reperfusion. We did not find any impact of
smoking on myocardial perfusion and scintigraphic infarct size.
The application of reperfusion therapies has largely contributed
to the relevant reduction in mortality observed in the last decades
in the treatment of STEMI. Primary angioplasty and adjunctive
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Fig. 3. Bar graphs show the impact of smoking on infarct size (as percentage of pa-
tients above the median).
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Fig. 1. Bar graphs show the impact of smoking on infarct size. Data are presented as
median [25the75th percentile].
G. De Luca et al. / Atherosclerosis 233 (2014) 145e148 147antithrombotic therapies [17e19], have further contributed to
improve survival.
Several studies have shown that smoking, despite being asso-
ciated with higher occurrence of CAD and STEMI, among STEMI
patients it is associated with improved survival as compared to
nonsmokers, the so called “smoker’s paradox”. This finding has
been initially observed among patients treated with thrombolysis
[8e12], and some of the explanations were the lower prevalence of
risk factors in smokers and the different composition of the infarct-
related lesion, with a large prevalence of thrombotic component
and less atherosclerotic background. Few data have been reported
among patients undergoing mechanical reperfusion, when the
presence of larger thrombotic component may imply higher risk of
impaired myocardial reperfusion and larger infarct size. Hasdai
et al. [20] found from analysis of the GUSTO IIb study that primary
angioplasty was associated with a better 30-day outcome than
tissue-type plasminogen activator regardless of smoking status and
should be considered when readily available. In another report,
Weisz et al. [21] found that smokers had greater survival compared
to nonsmokers or former smokers, both at 30 days and at 1 year of
follow-up. In addition, rates of reinfarction were lower in current0
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Fig. 2. Bar graphs show the impact of smoking on infarct size according to the pro-
pensity score. Data are presented as median [25the75th percentile].smokers during the 1-year follow-up period, resulting in lower
composite rates of major adverse cardiac events in cigarette users.
Indeed, a doseeresponse curve was evident, with the greatest
apparent protection from mortality and reinfarction in those who
smoked the most. The improved prognosis in smokers with STEMI
after primary PCI could nearly entirely be explained by differences
in baseline clinical and angiographic features. Active smokers with
STEMI were younger than nonsmokers and had lower rates of
diabetes mellitus and hypertension, variables known to have an
important impact on survival after STEMI [22,23]. Moreover, non-
smokers were more likely to be women and had higher rates of
triple-vessel CAD and LAD involvement, factors also known to
negatively influence prognosis after myocardial infarction [24].
When these baseline differences were corrected for by multivariate
analysis, smoking status was no longer an independent predictor of
survival. Similarly, in a recent study including 1424 STEMI patients
undergoing rescue or primary angioplasty, Wakabayashi et al. [25],
found a beneficial effect of smoking on clinical outcome, that dis-
appeared after adjustment for differences in baseline characteris-
tics. However, Katayama et al. [26], among 367 STEMI patients
undergoing primary angioplasty, found that smoking was associ-
ated with lower mortality rates, potentially explained by less
damage to the microvascular function (as evaluated by ST-segment
resolution) and better ejection fraction. Similar results were found
by Albertal et al. [27], who analyzed 140 STEMI patients undergoing
primary angioplasty. In fact, multivariate logistic regression anal-
ysis identified active smoking as an independent predictor of
complete STR at 60 min (OR 3.47; 95% CI 1.48e8.14; p ¼ 0.004).
This is the largest study evaluating the impact of smoking on
infarct size as evaluated by nuclear techniques. We found that
smokers had a lower risk profile as compared to non-smokers. No
difference was observed in scintigraphic infarct size, confirmed
after correction for baseline confounding factors.
4.1. Study limitations
Patient reporting of smoking status may not have been accurate
in all cases. Furthermore, patients were categorized as active
smokers or non-smokers at the time of hospital admission, and
therefore no information was collected on previous smokers. We
assessed the infarct size at 1 month after index infarction instead of
at hospital discharge, as in the majority of previously published
studies. On the other hand, this circumstance should be more
effective in preventing interference of myocardial stunning with
the extent of perfusion defects [28]. Moreover, the execution of a
G. De Luca et al. / Atherosclerosis 233 (2014) 145e148148coronary angiographic control before gated SPECT allowed the
exclusion of infarct-related vessel restenosis. The availability of
outcome data at 1 year follow-up would have improved our results
Unfortunately, data were not available from all patients and
therefore not included. However, this is a relatively selected cohort
of patients, being included in randomized trials and 30-day survi-
vors. Finally, we studied a patient population submitted to a very
aggressive revascularisation protocol, including early direct
percutaneous coronary intervention. Therefore, caution should be
exercised in extending our data to infarct patients treated with
other reperfusion strategies.5. Conclusions
This study showed that among STEMI patients undergoing pri-
mary angioplasty, smoking does not affect scintigraphic infarct size.References
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